This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.
-
Working with individual set: COAD-TP
-
Number of patients in set: 154
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:COAD-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 20
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
nnon = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | APC | adenomatous polyposis coli | 8592 | 1 | 0 | 4 | 23 | 102 | 0 | 38 | 163 | 107 | 108 | 1.6e-15 | 0.00019 | 0.97 | 1e-16 | 6.1e-13 |
2 | TP53 | tumor protein p53 | 1889 | 54 | 0 | 1 | 49 | 13 | 0 | 13 | 75 | 73 | 49 | 1e-16 | 0.0012 | 1e-05 | 1e-16 | 6.1e-13 |
3 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 709 | 17 | 0 | 0 | 59 | 0 | 0 | 0 | 59 | 59 | 9 | 1e-16 | 1e-05 | 0.0042 | 1e-16 | 6.1e-13 |
4 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 941 | 34 | 0 | 0 | 15 | 0 | 0 | 0 | 15 | 15 | 7 | 5.3e-13 | 1e-05 | 0.019 | 2.2e-16 | 1e-12 |
5 | SMAD4 | SMAD family member 4 | 1699 | 74 | 0 | 0 | 17 | 3 | 0 | 2 | 22 | 18 | 18 | 1.8e-12 | 0.11 | 0.0063 | 5.4e-13 | 2e-09 |
6 | FBXW7 | F-box and WD repeat domain containing 7 | 2580 | 4 | 0 | 2 | 26 | 6 | 0 | 1 | 33 | 29 | 21 | 1.5e-11 | 0.001 | 0.51 | 1.1e-12 | 3.3e-09 |
7 | SMAD2 | SMAD family member 2 | 1444 | 57 | 0 | 1 | 7 | 4 | 0 | 0 | 11 | 10 | 8 | 8.9e-08 | 0.0014 | 0.073 | 1.7e-09 | 4.5e-06 |
8 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 2371 | 12 | 0 | 0 | 21 | 0 | 0 | 0 | 21 | 20 | 3 | 0.00015 | 1e-05 | 0.0048 | 3.1e-08 | 0.000071 |
9 | FAM123B | family with sequence similarity 123B | 3412 | 27 | 0 | 1 | 5 | 11 | 0 | 3 | 19 | 19 | 17 | 4.9e-09 | 0.5 | 0.51 | 9.9e-08 | 0.0002 |
10 | MGC42105 | 1319 | 47 | 0 | 1 | 8 | 2 | 0 | 0 | 10 | 10 | 10 | 5.9e-09 | 1 | 0.98 | 1.2e-07 | 0.00022 | |
11 | ACVR1B | activin A receptor, type IB | 1679 | 9 | 0 | 0 | 12 | 0 | 0 | 1 | 13 | 13 | 13 | 2.9e-06 | 0.26 | 0.023 | 2e-06 | 0.0033 |
12 | DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | 5059 | 20 | 0 | 3 | 11 | 0 | 0 | 1 | 12 | 12 | 9 | 0.18 | 0.00018 | 0.11 | 0.000026 | 0.038 |
13 | PCBP1 | poly(rC) binding protein 1 | 1071 | 67 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 2 | 0.02 | 0.0001 | 0.021 | 0.000028 | 0.038 |
14 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 2565 | 12 | 0 | 2 | 9 | 2 | 0 | 0 | 11 | 10 | 6 | 0.0076 | 0.00011 | 1 | 0.000029 | 0.038 |
15 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 3287 | 3 | 0 | 1 | 33 | 0 | 0 | 0 | 33 | 26 | 18 | 0.24 | 1e-05 | 0.00026 | 0.000033 | 0.04 |
16 | BCOR | BCL6 co-repressor | 5324 | 0 | 0 | 2 | 3 | 3 | 0 | 1 | 7 | 6 | 7 | 0.0015 | 1 | 0.00038 | 0.000039 | 0.044 |
17 | ZHX2 | zinc fingers and homeoboxes 2 | 2518 | 6 | 0 | 0 | 5 | 1 | 0 | 2 | 8 | 8 | 7 | 0.000027 | 0.13 | 0.5 | 0.000056 | 0.06 |
18 | KLHL5 | kelch-like 5 (Drosophila) | 2308 | 5 | 0 | 0 | 4 | 1 | 0 | 2 | 7 | 5 | 5 | 0.0021 | 0.0034 | 0.048 | 0.000082 | 0.078 |
19 | CASP8 | caspase 8, apoptosis-related cysteine peptidase | 1749 | 9 | 0 | 0 | 7 | 2 | 0 | 2 | 11 | 10 | 10 | 0.000026 | 0.36 | 0.36 | 0.000083 | 0.078 |
20 | PCDHGB1 | protocadherin gamma subfamily B, 1 | 45770 | 13 | 0 | 0 | 7 | 1 | 0 | 0 | 8 | 7 | 8 | 6.6e-06 | 1 | 0.9 | 0.000085 | 0.078 |
21 | UBXN11 | UBX domain protein 11 | 1713 | 70 | 0 | 1 | 1 | 0 | 0 | 4 | 5 | 3 | 3 | 0.091 | 6e-05 | 0.78 | 0.00013 | 0.11 |
22 | MIER3 | mesoderm induction early response 1, family member 3 | 1700 | 9 | 0 | 0 | 6 | 2 | 0 | 2 | 10 | 10 | 10 | 0.000014 | 1 | 0.64 | 0.00017 | 0.15 |
23 | TBC1D10C | TBC1 domain family, member 10C | 1379 | 43 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 1 | 0.017 | 0.001 | 0.99 | 0.0002 | 0.16 |
24 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 2138 | 14 | 0 | 3 | 8 | 4 | 0 | 1 | 13 | 11 | 13 | 0.000076 | 0.2 | 0.48 | 0.0002 | 0.16 |
25 | PCDHGA9 | protocadherin gamma subfamily A, 9 | 22888 | 12 | 0 | 0 | 4 | 1 | 0 | 0 | 5 | 5 | 5 | 0.000031 | 1 | 0.57 | 0.00024 | 0.17 |
26 | PCDHGA7 | protocadherin gamma subfamily A, 7 | 31478 | 14 | 0 | 1 | 4 | 1 | 0 | 0 | 5 | 5 | 4 | 0.00044 | 0.084 | 0.37 | 0.00026 | 0.18 |
27 | KLK2 | kallikrein-related peptidase 2 | 841 | 67 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 | 0.026 | 0.001 | 0.53 | 0.0003 | 0.2 |
28 | ESR1 | estrogen receptor 1 | 1820 | 14 | 0 | 0 | 10 | 2 | 0 | 0 | 12 | 11 | 12 | 3e-05 | 1 | 0.74 | 0.00035 | 0.22 |
29 | PCDHA3 | protocadherin alpha 3 | 30618 | 13 | 0 | 0 | 13 | 0 | 0 | 0 | 13 | 10 | 12 | 0.00027 | 0.24 | 0.4 | 0.00035 | 0.22 |
30 | HCLS1 | hematopoietic cell-specific Lyn substrate 1 | 1511 | 28 | 0 | 2 | 4 | 2 | 0 | 1 | 7 | 7 | 6 | 0.00044 | 0.28 | 0.16 | 0.00051 | 0.31 |
31 | GGA2 | golgi associated, gamma adaptin ear containing, ARF binding protein 2 | 1908 | 21 | 0 | 1 | 4 | 3 | 0 | 1 | 8 | 8 | 8 | 0.00033 | 1 | 0.086 | 0.00066 | 0.38 |
32 | MYH11 | myosin, heavy chain 11, smooth muscle | 6141 | 88 | 0 | 4 | 18 | 2 | 0 | 1 | 21 | 16 | 21 | 0.00014 | 1 | 0.26 | 0.00069 | 0.38 |
33 | RNF43 | ring finger protein 43 | 2384 | 92 | 0 | 1 | 9 | 0 | 0 | 2 | 11 | 10 | 10 | 0.00042 | 0.19 | 0.6 | 0.00073 | 0.38 |
34 | CREBBP | CREB binding protein (Rubinstein-Taybi syndrome) | 7449 | 98 | 0 | 6 | 16 | 4 | 0 | 1 | 21 | 17 | 21 | 7e-05 | 1 | 0.89 | 0.00074 | 0.38 |
35 | PCDHGB5 | protocadherin gamma subfamily B, 5 | 24615 | 13 | 0 | 0 | 7 | 0 | 0 | 0 | 7 | 6 | 7 | 0.000072 | 1 | 0.47 | 0.00076 | 0.38 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.